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Estrogen receptor α (ERα) is liable for regulating transcription factors which are an 
important part of hormonal signaling in breast cancer. This study intends to find hit 
compounds that are considered capable of inhibiting ERα by utilizing structure-based 
pharmacophores and molecular docking. Pharmacophore of the original ERα ligand 
(E4D600) has one hydrogen bond acceptor and three hydrogen bond donors which are 
used to select compounds from the Indonesian herbal database. This pharmacophore 
model had an Area under Curve of the Receiver Operating Characteristics (AUC-ROC) 
value is 0.80 and the Goodness of Hits (GH) value is 0.81. The selection process 
generated 330 compounds which proceed to the molecular docking stage to analyze 
their binding energy and interactions to ERα. The results indicated potential hit 
compounds seen from their binding energies in the range -5.42 to -10.01 kcal/mol. four 
of the best compounds including Lig57/(-)-Bidwillon A, Lig47/Quercetin 3-(6''-
galloylgalactoside), Lig197/Multifloroside and Lig83/Erythrabyssin II provide promising 
information for their detailed analysis as ERα inhibitors. 
 





Estrogen receptor α (ERα) bertanggung jawab dalam mengatur faktor transkripsi yang 
berperan penting pada jalur pensinyalan hormonal kanker payudara. Penelitian ini 
bermaksud untuk menemukan senyawa yang dianggap mampu menghambat ERα 
dengan memanfaatkan pemodelan farmakofor berbasis struktur dan penambatan 
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molekuler. Farmakofor Ligan alami ERα (E4D600) memiliki satu akseptor ikatan hidrogen 
dan tiga donor ikatan hidrogen yang digunakan untuk memilih senyawa dari database 
herbal Indonesia. Model farmakofor ini memiliki nilai Area under Curve of Receiver 
Operating Characteristics (AUC-ROC) sebesar 0,8 dan nilai Goodness of Hits (GH) sebesar 
0,81. Penambatan molekuler terhadap 330 senyawa hit bertujuan untuk menganalisis 
energi ikatan dan interaksinya dengan ERα. Hasil penambatan molekuler menunjukkan 
potensi dari senyawa hit berdasarkan energi ikatannya dengan rentang -5,42 hingga -
10,01 kkal/mol. Empat senyawa terbaik di antaranya Lig57/(-)-Bidwillon A, 
Lig47/Quercetin 3-(6''-galloylgalactoside, Lig197/Multifloroside, dan Lig83/Erythrabyssin 
II memberikan informasi yang menjanjikan untuk analisis lebih terperinci senyawa hit 
tersebut sebagai inhibitor ERα. 
 





Indonesia has a variety of plants 
and compounds that have long been 
used until now to treat various types of 
diseases (Sholikhah, 2016).  Cancer is 
one of the causes of death in Indonesia 
(Tjindarbumi and Mangunkusumo, 
2002). Cancer, one of which can be 
caused by abnormalities of estrogen 
receptor expression(Hua et al., 2018). 
The expression of the estrogen receptor 
can be a parameter for the diagnosis of 
breast cancer (Haque and Desai, 2019). 
Estrogen receptors (ER) are 
mediators of intracellular signaling 
pathways and transcription factors 
involved in many parts of the biological 
system, including cell expansion and 
regulating the central nervous system, 
mammary glands, and reproduction. 
Estrogen receptors consist of 2 types 
encoded by different genes and 
activated by estrogens, namely ERα and 
ERβ (Souza et al., 2017). ERα can be 
found in the breast, bone, and 
reproductive tissue (uterus, ovary). ERα 
plays a role in tumorigenesis and the 
expansion of breast cancer. ERβ is found 
in the prostate, large intestine, immune 
system, cardiovascular system, and 
central nervous system. ERβ can directly 
inhibit the activity and expression of ERα 
(Jia et al., 2015). The most frequent and 
effective treatment given to breast 
cancer sufferers is with a selective 
estrogen receptor modulator (SERM) 
(Grande et al., 2018).  
Tamoxifen, toremifene, 
raloxifene, and arzoxifene are SERM 
groups that block estrogen from 
occupying with its receptor. the group 
has many problems including side effects 
such as stroke, heart disease, coronary 
events, bone fractures, low 
bioavailability, mutations that cause a 
high risk of breast cancer recurrence, 
and even death (Kucinska et al., 2016; 
Piperigkou and Karamanos, 2020; Dai 
and Wu, 2011; Zheng et al., 2020). This 
study aims to identify Indonesian natural 
compounds that have the potential to 
inhibit estrogen receptors by utilizing 
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virtual screening techniques along with 
the development of science and 
technology. 
Virtual screening is a computer-
aided drug design technique (CADD) in 
drug discovery that utilizes 
pharmacophores ligand information to 
obtain active compounds (ligand-based 
drug design) (Makrynitsa et al., 2018). 
The structure-based drug design 
included in CADD namely molecular 
docking (Batool, Ahmad, and Choi 2019) 
was also applied in this study to explore 
and analyze the binding energy and 
orientation of the hit compound on the 
estrogen receptor. 
 
Material and Methods 
Pharmacophore modeling and data base 
screening  
LigandScout Advanced 4.3 
(Wolber and Langer, 2005) was used to 
build a pharmacophore model of the 
E4D600 structure which is a native ligand 
from ERΑ (PDB ID: 1SJ0). The 
pharmacophore model generated was 
validated against 626 active compounds 
and 20773 decoys obtained from the 
Directory of Useful Decoys: Enhanced 
(DUD-E) (http://www.dude.docking.org/) 
(Mysinger et al., 2012).  The best 
pharmacophore model chosen had 
features with one hydrogen bond 
acceptor and three hydrogen bond 
donors (Figure 1).  These features are 
then used for screening compounds in 
the Indonesian Herbal database 
(http://herbaldb.farmasi.ui.ac.id/). 
Molecular docking simulation 
All hit compounds were 
subjected to molecular docking 
simulation using iDock software. iDock is 
a software under the apache 2.0 license 
which is available free of charge and 
open source (Li, et al., 2012) to ERα. ERα 
protein was downloaded from protein 
data bank (PDB ID: 1SJ0) 
(http://www.rcsb.org/pdb/). The protein 
was prepared by removing water 
molecules, added polar hydrogen, and 
the Kollman charge using AutoDockTools 
1.5.6 software (Morris et al., 2009; Arba 
et al., 2018; Arba et al., 2018). The active 
site of the protein was regulated by 
copying the position of native ligands 
with coordinates center x = 30.660, 
center y = -1.067 dan center z = 23,464. 
The grid box size used is 40 x 40 x 40 Å 
with point spacing 0.375 Å. The results of 
molecular docking are then visualized 
using Discovery Studio Visualizer. 
 
Result and Discussion 
The pharmacophore model was 
chosen must fulfill the AUC-ROC and GH 
score criteria greater than or equal to 
0.5. The best pharmacophore model was 
generated had features with one 
hydrogen bond acceptor and three 
hydrogen bond donors (Figure 1). The 
pharmacophore model fulfills the 
validation requirements with a Goodness 
of Hits (GH) value is 0.81 and an Area 
Under Curve value of the Receiver 
Operating Characteristic (AUC-ROC) is 
0.80 (Figure 2). AUC-ROC values close to 
1 indicate the good pharmacophore 
model and could be distinguishing 
between active and decoy compounds. 
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Further, screening against the 
Indonesian Herbal database (1379 
molecules) employing the validated 
pharmacophore model retrieved 330 hit 
molecules.  
The interactions of 330 hit 
compounds were analyzed using 
molecular docking results based on their 
binding energy and conformation to 
ERΑ. Validation of the molecular docking 
process was achieved by obtaining a root 
mean square deviation (RMSD) value 
from the overlay between the 
crystallographic conformation of the 
native ligand (E4D600) and the docking 
result are 0.6252 Å (Figure 3).  
Molecular docking on all hits to 
ERα resulted in conformations and 
binding energies in the interval of -5.42 
to -10.01 kcal/mol. The binding energies 
of hit molecules were comparable to 
that of the ligand antagonist 4-D (-11.81 
kcal/mol). Some interactions observed 
from the conformation of E4D600 
include interactions with hydrogen 
bonds with residues Gly521, His524, 
Leu387, Glu353, and Arg394. The 
conformation also has interactions with 
Leu384, Leu349, Met421, and Leu354. It 
is known that His524, Leu348, and 
Met421 are important residues on the 
ERα active site (Kim et al., 2004).  
Based on the binding energies 
and conformations, four best-docked hit 
molecules were selected. They were 
Lig57 or (-)-Bidwillon A (E = -10.01 
kcal/mol), Lig47 or Quercetin 3-(6''-
galloylgalactoside (E = -10.00 kcal/mol), 
Lig197 or Multifloroside (E = -9.87 
kcal/mol), and Lig83 or Erythrabyssin II 
(E = -9.69 kcal/mol). Figure 4 shows the 
chemical structures of the four best 




Figure 1. 3D pharmacophore model 
composed of one hydrogen 
bond acceptor (red line) and 
three hydrogen bond donor 





Figure 2. The Area under Curve (AUC) of 
Receiver Operating 
Characteristic (ROC) curve 
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Figure 3. The superimposed 3D 
conformations of both 
experimental (purple) and 
docked (blue) experiments with 
green dash line represent the 
hydrogen bond 
 
The interaction of Lig47 or 
Quercetin 3-(6''-galloylgalactoside) with 
ERΑ was supported by hydrogen bonds 
with Glu353 and Gly521 residues, while 
hydrophobic interactions were observed 
with Leu384, Leu387, His524, Leu525. 
Leu349. In Lig57 or (-)-Bidwillon A, the 
interaction with ERα was dominated by 
hydrophobic interactions with residues 
Glu353, His524, Leu384, Leu387, Leu525, 
Leu349. 
Hydrogen bonds in Lig197 or 
Multifloroside interact with Gly420, 
Gly521, Ile424 residues, as well as in 
Lig83 or Erythrabyssin II interact with 
Glu353, Arg394, Ile424, Leu387 residues 
on the active site of ERα. Hydrophobic 
Interactions with residues His524, 
Leu525, Leu384, and Met421 were 
observed in both ligands. All hit 
compounds can interact with important 
residues on the active site of ERΑ. Figure 
5 shows the conformation and 




Figure 4. The chemical structures of the four best docked hit molecules 
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Figure 5. The binding orientation of Quercetin 3- (6''-galloylgalactoside), (-)-Bidwillon A, 
Erythrabyssin II, and Multifloroside in the active site of ERα 
 
Conclusion 
This study was effectively able to 
identify potential estrogen receptor 
inhibitors from the Indonesian herbal 
database which contained 1379 
molecules. This illustrates that all the 
best compounds were able to occupy 
the active site of ERα as showed by 
molecular docking simulations. The 
binding energy of four best hits      
(Lig57/(-)-Bidwillon A, Lig47/Quercetin 3-
(6''-galloylgalactoside), 
Lig197/Multifloroside and 
Lig83/Erythrabyssin II), were comparable 
with native ligand E4D600. It represents 
their potential to inhibit ERα and to be 
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